Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

As of the November 25, 2025 data cutoff in the open-label Phase 2 portion of TUPELO, treatment with REC-4881 (4 mg QD) ...

Materials informatics combines data analytics and engineering design, streamlining material development and enhancing ...

But there’s a big problem — DeepSeek does not appear to have conducted any predeployment safety testing. There is no mention ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

A new NURBS-based algorithm is revolutionizing gridshell design by enabling faster, smoother, and more flexible shape-finding. What once required 90 hours of GPU time now takes just 90 minutes on a ...

AI promises to make hiring fairer by reducing human bias, yet it often reshapes what fairness means—and locks in one definition. A three-year study of a global consumer-goods firm found that their ...